Clinical trials: Simvastatin
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
- Trial name
- NCT01342211
- Testing
- Statin, PF-04950615 (RN316), Satin
- Where
- 44 sites in United States, Canada
- Volunteers
- 93 people
- Sponsor
- Pfizer
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Serious Mental Illness, Schizophrenia
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
Patients with severe mental illness (SMI) die younger than persons in the general population. Much of the excess mortality for SMI patients is attributable to cardiovascular disease, and is exacerbated by treatment with…
- Conditions
- Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- FITNESS (NCT02188121)
- Testing
- Simvastatin, Losartan
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mclean Hospital
Hypercholesterolemia, Myocardial Infarction
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40…
- Trial name
- NCT00202878
- Testing
- ezetimibe/simvastatin, simvastatin
- Volunteers
- 18,144 people
- Sponsor
- Organon and Co
Kidney Disease, Chronic
Study of Heart and Renal Protection
The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for…
- Trial name
- SHARP (NCT00125593)
- Testing
- Simvastatin 20 mg, Ezetimibe 10mg
- Where
- United Kingdom
- Volunteers
- 9,438 people
- Sponsor
- University of Oxford
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- ODYSSEY FH I (NCT01623115)
- Testing
- Alirocumab, Lipid Modifying Therapy (LMT)
- Where
- 91 sites in United States, Austria and 12 more
- Volunteers
- 486 people
- Sponsor
- Sanofi
Cardiovascular Disease
Polypill For Prevention of Cardiovascular Disease
The purpose of this pilot study is to provide data on the feasibility of conducting a large clinical trial on the polypill (combination of aspirin, angiotensin converting enzyme inhibitor, thiazide diuretic, and statin) for…
- Trial name
- NCT00567307
- Testing
- Red Heart Pill 2b (Polypill), Standard Practice
- Where
- 3 sites in Sri Lanka
- Volunteers
- 216 people
- Sponsor
- Wake Forest University Health Sciences
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer
The purpose of this pilot phase II trial is to identify the molecular and genetic mechanisms by which statins influence breast cancer cell proliferation.
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT03454529
- Testing
- Laboratory Biomarker Analysis, Simvastatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Michael Simon
Hypercholesterolemia
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison to ezetimibe 10 mg daily after 24…
- Trial name
- ODYSSEY EAST (NCT02715726)
- Testing
- Alirocumab, ezetimibe, atorvastatin
- Where
- 62 sites in China, India and 1 more
- Volunteers
- 615 people
- Sponsor
- Sanofi
Diabetic Retinopathy
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various…
- Trial name
- NCT00542178
- Testing
- Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,472 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Peripheral Artery Disease
Comprehensive Magnetic Resonance of Peripheral Arterial Disease
The purpose of this study is to develop new ways of imaging fatty blockages in the leg arteries to improve upon techniques used now and to develop new ways of understanding how new treatments may affect the disease.
- Trial name
- NCT00587678
- Testing
- Simvastatin, Ezetimibe, Simvastatin/Ezetimibe
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Virginia
Hypercholesterolemia
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01507831
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 320 sites in United States, Argentina and 25 more
- Volunteers
- 2,341 people
- Sponsor
- Sanofi
Perioperative Inflammatory Response
Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery
The purpose of the present study is to quantify the degree of modulation, if any, in the perioperative inflammatory response associated with statins use.
- Trial name
- NCT00656292
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197234
- Testing
- Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study of LY2623091 in Healthy Participants
The first purpose of this study is to evaluate the effect of itraconazole (and possibly diltiazem) on the amount of LY2623091 in the blood stream and how long the body takes to get rid of it.
- Trial name
- NCT02300259
- Testing
- LY2623091, Itraconazole, Simvastatin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia
A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)
Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea.
- Trial name
- NCT00496730
- Testing
- simvastatin (+) ezetimibe, Comparator: atorvastatin
- Volunteers
- 256 people
- Sponsor
- Organon and Co
Hypercholesterolemia
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.
- Trial name
- NCT00271817
- Testing
- Comparator: ezetimibe/simvastatin + niacin (ER), Comparator: niacin (ER) tablet, Comparator: ezetimibe (+) simvastatin
- Volunteers
- 1,220 people
- Sponsor
- Organon and Co
Dyslipidemias
The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin
Both XueZhiKang and Statins are cholesterol-lowering medications that are often prescribed for individuals with high cholesterol and who are at risk for cardiovascular disease (CVD).
- Trial name
- NCT01686451
- Testing
- XueZhiKang, simvastatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wenzhou Medical University
Secondary Progressive Multiple Sclerosis
Simvastatin in Secondary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a neurological condition which is a common cause of disability in young people. It is thought to be an autoimmune condition, where the body's immune system begins to attack itself.
- Trial name
- MS-OPT (NCT03896217)
- Testing
- Simvastatin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College, London
Carotid Atherosclerosis
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
This study will examine the effect of statin and niacin therapy on carotid plaque biomarkers
- Trial name
- MCAT (NCT00804843)
- Testing
- Atorvastatin/niacin extended-release, Atorvastatin, Simvastatin
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC